Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.
Moschos SJ, Sullivan RJ, Hwu WJ, Ramanathan RK, Adjei AA, Fong PC, Shapira-Frommer R, Tawbi HA, Rubino J, Rush TS 3rd, Zhang D, Miselis NR, Samatar AA, Chun P, Rubin EH, Schiller J, Long BJ, Dayananth P, Carr D, Kirschmeier P, Bishop WR, Deng Y, Cooper A, Shipps GW, Moreno BH, Robert L, Ribas A, Flaherty KT. Moschos SJ, et al. Among authors: tawbi ha. JCI Insight. 2018 Feb 22;3(4):e92352. doi: 10.1172/jci.insight.92352. eCollection 2018 Feb 22. JCI Insight. 2018. PMID: 29467321 Free PMC article. Clinical Trial.
Reply to A. Shinde et al.
Kluger HM, Margolin KA, Davies MA, Long GV, Tawbi HA, Goldberg SB, Chiang VL. Kluger HM, et al. J Clin Oncol. 2019 Apr 20;37(12):1031-1032. doi: 10.1200/JCO.18.02463. Epub 2019 Feb 26. J Clin Oncol. 2019. PMID: 30807233 No abstract available.
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.
Sullivan RJ, Hamid O, Gonzalez R, Infante JR, Patel MR, Hodi FS, Lewis KD, Tawbi HA, Hernandez G, Wongchenko MJ, Chang Y, Roberts L, Ballinger M, Yan Y, Cha E, Hwu P. Sullivan RJ, et al. Nat Med. 2019 Jun;25(6):929-935. doi: 10.1038/s41591-019-0474-7. Epub 2019 Jun 6. Nat Med. 2019. PMID: 31171876 Clinical Trial.
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.
Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA; International Neoadjuvant Melanoma Consortium members; Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV. Amaria RN, et al. Among authors: tawbi ha. Lancet Oncol. 2019 Jul;20(7):e378-e389. doi: 10.1016/S1470-2045(19)30332-8. Lancet Oncol. 2019. PMID: 31267972 Review.
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce.
Kluger HM, Tawbi HA, Ascierto ML, Bowden M, Callahan MK, Cha E, Chen HX, Drake CG, Feltquate DM, Ferris RL, Gulley JL, Gupta S, Humphrey RW, LaVallee TM, Le DT, Hubbard-Lucey VM, Papadimitrakopoulou VA, Postow MA, Rubin EH, Sharon E, Taube JM, Topalian SL, Zappasodi R, Sznol M, Sullivan RJ. Kluger HM, et al. Among authors: tawbi ha. J Immunother Cancer. 2020 Mar;8(1):e000398. doi: 10.1136/jitc-2019-000398. J Immunother Cancer. 2020. PMID: 32238470 Free PMC article.
The State of Melanoma: Emergent Challenges and Opportunities.
Atkins MB, Curiel-Lewandrowski C, Fisher DE, Swetter SM, Tsao H, Aguirre-Ghiso JA, Soengas MS, Weeraratna AT, Flaherty KT, Herlyn M, Sosman JA, Tawbi HA, Pavlick AC, Cassidy PB, Chandra S, Chapman PB, Daud A, Eroglu Z, Ferris LK, Fox BA, Gershenwald JE, Gibney GT, Grossman D, Hanks BA, Hanniford D, Hernando E, Jeter JM, Johnson DB, Khleif SN, Kirkwood JM, Leachman SA, Mays D, Nelson KC, Sondak VK, Sullivan RJ, Merlino G; Melanoma Research Foundation. Atkins MB, et al. Among authors: tawbi ha. Clin Cancer Res. 2021 May 15;27(10):2678-2697. doi: 10.1158/1078-0432.CCR-20-4092. Epub 2021 Jan 7. Clin Cancer Res. 2021. PMID: 33414132 Free PMC article.
Development of Immunotherapy Combination Strategies in Cancer.
Yap TA, Parkes EE, Peng W, Moyers JT, Curran MA, Tawbi HA. Yap TA, et al. Cancer Discov. 2021 Jun;11(6):1368-1397. doi: 10.1158/2159-8290.CD-20-1209. Epub 2021 Apr 2. Cancer Discov. 2021. PMID: 33811048 Free PMC article. Review.
The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020.
Ascierto PA, Atkins MB, Eggermont AM, Gershenwald JE, Grob JJ, Hamid O, Sondak VK, Sosman JA, Tawbi HA, Weber JS, Caracò C, Osman I, Puzanov I. Ascierto PA, et al. J Transl Med. 2021 Apr 7;19(1):142. doi: 10.1186/s12967-021-02808-3. J Transl Med. 2021. PMID: 33827575 Free PMC article.
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses.
Friedman CF, Spencer C, Cabanski CR, Panageas KS, Wells DK, Ribas A, Tawbi H, Tsai K, Postow M, Shoushtari A, Chapman P, Karakunnel J, Bucktrout S, Gherardini P, Hollmann TJ, Chen RO, Callahan M, LaVallee T, Ibrahim R, Wolchok J. Friedman CF, et al. Among authors: tawbi h. J Immunother Cancer. 2022 Jan;10(1):e003853. doi: 10.1136/jitc-2021-003853. J Immunother Cancer. 2022. PMID: 35074903 Free PMC article. Clinical Trial.
205 results